Pages that link to "Q35742631"

The following pages link to Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities (Q35742631):

Displaying 48 items.

• Mutant p53 and ETS2, a Tale of Reciprocity (Q26765746) (← links)
• Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways (Q26767396) (← links)
• Mutant p53: One, No One, and One Hundred Thousand (Q26770576) (← links)
• p53 as a Regulator of Lipid Metabolism in Cancer (Q28079393) (← links)
• Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. (Q30354662) (← links)
• Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma (Q33618850) (← links)
• The ETS family of oncogenic transcription factors in solid tumours. (Q34555986) (← links)
• The Emerging Hallmarks of Cancer Metabolism (Q36468964) (← links)
• Characterization of cancer-associated missense mutations in MDM2. (Q36998050) (← links)
• Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation (Q37022218) (← links)
• Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia (Q37273793) (← links)
• Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. (Q37418541) (← links)
• Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. (Q39005896) (← links)
• Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. (Q39249420) (← links)
• Molecularly targeted therapies for p53-mutant cancers (Q39393193) (← links)
• Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. (Q40223279) (← links)
• Learning causal networks with latent variables from multivariate information in genomic data (Q42696657) (← links)
• Control of Nucleotide Metabolism Enables Mutant p53's Oncogenic Gain-of-Function Activity (Q47238975) (← links)
• Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism. (Q47674627) (← links)
• Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. (Q51679220) (← links)
• SUMO2 modification of Aurora B and its impact on follicular development and atresia in the mouse ovary. (Q52364703) (← links)
• Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. (Q52584348) (← links)
• KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration. (Q52691555) (← links)
• Paris Polyphylla-Derived Saponins Inhibit Growth of Bladder Cancer Cells by Inducing Mutant P53 Degradation While Up-Regulating CDKN1A Expression. (Q52716922) (← links)
• Emerging Non-Canonical Functions and Regulation of p53. (Q52723171) (← links)
• Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease. (Q53688741) (← links)
• dNTP metabolism links mechanical cues and YAP/TAZ to cell growth and oncogene-induced senescence. (Q53695910) (← links)
• Complexes formed by mutant p53 and their roles in breast cancer. (Q55333537) (← links)
• Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells (Q57461582) (← links)
• Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development (Q58114021) (← links)
• Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism (Q58789576) (← links)
• Emodin, Physcion, and Crude Extract of var. Induce Mixed Cell Death, Increase in Oxidative Stress, DNA Damage, and Inhibition of AKT in Cervical and Oral Squamous Carcinoma Cell Lines (Q59512041) (← links)
• Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness (Q62057894) (← links)
• Drugging in the absence of p53 (Q64107799) (← links)
• Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides. (Q64899590) (← links)
• The tAnGo fell short of inspiring the audience (Q88010489) (← links)
• Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1 (Q88796735) (← links)
• Cyclin F is involved in response to cisplatin treatment in melanoma cell lines (Q89533295) (← links)
• Tumor suppressor p53 and metabolism (Q90003158) (← links)
• The Human Transient Receptor Potential Melastatin 2 Ion Channel Modulates ROS Through Nrf2 (Q90426204) (← links)
• Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors (Q91643844) (← links)
• p53: Multiple Facets of a Rubik's Cube (Q91672818) (← links)
• Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis (Q91817209) (← links)
• Efficient Modulation of TP53 Expression in Human Induced Pluripotent Stem Cells (Q92293773) (← links)
• Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma (Q92482661) (← links)
• Telomere attrition: metabolic regulation and signalling function? (Q92484283) (← links)
• MTA1-Dependent Anticancer Activity of Gnetin C in Prostate Cancer (Q93126607) (← links)
• p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities (Q93132946) (← links)